Announcements Trials

Browse Landscape

Phase

Phase 3 5 Phase NA 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 2 Classical hematology 2 Sarcoma 1 NET 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Endocrine 1 Dermatologic 1 Breast 1

Conditions

Melanoma 864 Lymphoma, T-Cell, Cutaneous 143 Uveal Melanoma 96 Skin Neoplasms 96 Mycosis Fungoides 95 Sezary Syndrome 81 Carcinoma, Basal Cell 76 Neoplasm Metastasis 68 Lymphoma 64 Lymphoma, Non-Hodgkin 63 Keratosis, Actinic 61 Neoplasms 57 Leukemia, Lymphocytic, Chronic, B-Cell 57 Carcinoma, Renal Cell 55 Carcinoma, Non-Small-Cell Lung 54 Lymphoma, B-Cell, Marginal Zone 53 Precursor Cell Lymphoblastic Leukemia-Lymphoma 52 Lymphoma, Mantle-Cell 52 Lymphoma, Large B-Cell, Diffuse 52 Lymphoma, Follicular 52 Hodgkin Disease 52 Lymphoma, Large-Cell, Immunoblastic 50 Carcinoma, Merkel Cell 50 Burkitt Lymphoma 49 Brain Neoplasms 46 Multiple Myeloma 44 Lymphoma, Large-Cell, Anaplastic 41 Recurrence 40 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40 Breast Neoplasms 40

Interventions

trametinib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fever × Dermatologic × Clear all

NCT01972347 2025-12-16

Neo Combi

Melanoma Institute Australia

Phase 2 Active not recruiting

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡